Nitrofurantoin in renal impairment

A 74 year old female patient presents to clinic describing dysuria and urinary frequency that started within the last few days.  She has no vaginal discharge or irritation and has no CVA tenderness, fevers, chills, flank pain, nausea, or vomiting.  The diagnosis of uncomplicated UTI is made based on clinical suspicion and you decide to prescribe some antibiotics.  She weighs 72 kg and her SCr is 1.4 mg/dL.  Using the Cockcroft-Gault equation,

Changes to FDA Pregnancy and Lactation Labeling

On December 3, 2014, the FDA issued a new rule revising the current regulations pertaining to the pregnancy, labor and delivery, and nursing mother sections of the prescribing information for prescription drugs and biologic products. Initiation of this amendment was prompted by the FDA’s goal to provide women and their healthcare providers with sufficient information when deciding which medications to prescribe in pregnant and breastfeeding patients.

^{Why the change?}

Recent data indicate that about 90% of pregnant women take at least one medication and 70% take one or more prescription drugs, potentially putting the fetus at high risk for drug-induced developmental abnormalities. Many pregnant women may also be on medications to control chronic disease states such as hypertension or to manage acute conditions developed during pregnancy such as gestational diabetes.  It is also necessary to consider that about half of all pregnancies are unexpected, leading to unintended drug exposure.

Foreign medication brand names

Let’s start with a patient case.  An elderly patient has recently arrived from Italy and you are performing the medication reconciliation from their home medication list.  Their medication list includes Flomax which may frequently be continued without hesitation.  In this example, however, Flomax is NOT the brand name for tamsulosin in Italy but rather the identical name for a different medication.